Clinical and Molecular Hepatology

"Yang-Hsiang Lin"

Reply to correspondence on “Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis”: Yang-Hsiang Lin, Ching-Chih Hu, Chih-Lang Lin; Clin Mol Hepatol 2026;32(3):e434-e436.
Published online February 5, 2026; DOI: https://doi.org/10.3350/cmh.2026.0123

Editorial

Challenges and innovations in MASLD and T2DM: Strengthening personalized medicine with SGLT2 inhibitors: Editorial on “Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis”: Yang-Hsiang Lin, Ching-Chih Hu, Chih-Lang Lin; Clin Mol Hepatol 2026;32(3):1417-1420.
Published online January 27, 2026; DOI: https://doi.org/10.3350/cmh.2026.0002

Citations

Citations to this article as recorded by

Reply to correspondence on “Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediat
Yang-Hsiang Lin, Ching-Chih Hu, Chih-Lang Lin
Clinical and Molecular Hepatology.2026; 32(3): e434. CrossRef
Correspondence to editorial on “Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-interme
Jonggi Choi, Raymond T. Chung
Clinical and Molecular Hepatology.2026; 32(3): e372. CrossRef